e-Therapeutics, a pioneering network pharmacology company focused on drug discovery and development, has appointed Dr Daniel Elger as chief financial officer (CFO).
Previously, Elger was vice president, marketing and communications at cancer drug developer Antisoma. He joined that company in 2002 and served on its senior management team from 2005, playing significant roles in corporate strategy, fundraisings and the acquisition of two US biotech companies. He also directed the investor relations strategy for the company.
Before Antisoma, Elger was a programme director for major pharmaceutical companies at a leading marketing and communications agency. He holds a BA in Physiological Sciences (Medicine) and a PhD in cancer cell biology, both from Oxford University.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.